balstilimab   Click here for help

GtoPdb Ligand ID: 14591

Synonyms: AGEN-2034 | AGEN2034 | AGEN2034w [6]
Compound class: Antibody
Comment: Balstilimab (AGEN2034) is an anti-PD-1 checkpoint inhibitor monoclonal antibody. Peptide sequences for the heavy and light chains of balstilimab are claimed in patent US10323091B2 [6], nominally for IgG4 antibody AGEN2034w.
No information available.
Summary of Clinical Use Click here for help
Dual treatment with balstilimab and botensilimab (AGEN-11810) is being investigated in advanced solid tumours, with a focus on treatment-refractory tumours, and those that are microsatellite-stable with low immunogenicity [1,3-5,7].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06346197 Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas Phase 3 Interventional Centre Leon Berard
NCT06279130 Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations Phase 2/Phase 3 Interventional The Netherlands Cancer Institute
NCT06322108 Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008) Phase 2 Interventional Immune Oncology Research Institute
NCT07152821 Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma Phase 3 Interventional Canadian Cancer Trials Group The BATTMAN study was terminated in mid-2026 as the developer changed focus away from microsatellite stable metastatic colorectal cancer and towards microsatellite stable colon cancer.
NCT03860272 Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer Phase 1 Interventional Agenus Inc. 2